Arcutis grants 57,000 RSUs under Nasdaq Rule 5635(c)(4)
Arcutis Biotherapeutics announced the grant of an aggregate 57,000 restricted stock units (RSUs) under Nasdaq Listing Rule 5635(c)(4).
WESTLAKE VILLAGE, Calif., Sept.
04, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.
NASDAQ:ARQT, a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 57,000 restricted stock units (RSUs…